Analyse aandeel Novartis

Novartis staat goed voorgesorteerd voor een stabiele groei op lange termijn. (Engelstalig rapport)

Damien Conover, CFA 24 april, 2014 | 0:14

INVESTMENT THESIS
In an industry plagued by stagnant growth, Novartis is well-positioned with diversified operating platforms and an industry-leading number of new potential blockbuster drugs. Strong intellectual property supporting multibillion-dollar products, combined with an abundance of late-pipeline products, creates a wide economic moat. While the late 2012 patent loss on Diovan and manufacturing problems in the consumer division will weigh on near-term growth, the company's strong strategic position should lead to steady long-term growth.

Novartis derives its strength from a diversified operating platform that includes branded pharmaceuticals, generics, eye-care products, and consumer products. Although the majority of its' competitors focus solely on the high-margin branded pharmaceutical segment, Novartis runs several complementary operations that reduce overall volatility and create cross-segment synergies. For example, not only does its generic business, Sandoz, serve to grab a portion of the billions of dollars in competitive branded products losing patent protection during the next 10 years, but it also extends the life cycle of in-house products as patents expire. Further, the acquisition of Alcon in 2011 greatly boosts Novartis' consumer and drug segments with additional sales from the fast-growing eye-care business.

The pharmaceutical segment is poised for long-term growth driven by new pipeline products and existing drugs. Novartis differentiates itself because of its sheer number of blockbusters, including Gilenya for multiple sclerosis, and Afinitor and Tasigna for cancer. Also, the company has generated a superior late-stage pipeline and should file several new products in 2014 in the United States and Europe. Despite the late 2012 Diovan patent loss and the eventual 2015 patent loss on Gleevec, the combination of a strong pipeline of new products and a diverse, well-positioned operating platform should translate into reliable growth over the long term.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

Om dit artikel te kunnen lezen, kunt u zich inschrijven als Morningstar Basic Member

Registreer gratis

Effecten genoemd in dit artikel

Naam effectPrijsChange (%)Morningstar Rating
Novartis AG ADR87,47 USD1,61
Pfizer Ltd INR4.180,00 INR0,00
Roche Holding AG334,85 CHF1,00

Over de auteur

Damien Conover, CFA  Damien Conover, CFA, is an associate director for Morningstar.

Bevestiging bezoeker


Onze website maakt gebruik van cookies en andere technologieën om een op u afgestemde ervaring te kunnen leveren, en te begrijpen hoe u en andere bezoekers onze website gebruiken. Zie 'cookie opties' voor verdere details.

  • Andere Morningstar websites
© Copyright 2018 Morningstar, Inc. Alle rechten voorbehouden.      Gebruiksvoorwaardenen      Privacybeleid.    Cookie toestemming
© Copyright 2020 Morningstar, Inc. Alle rechten voorbehouden.

Voorwaarden        Privacybeleid        Cookies